Randomized Controlled Trial
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 99272
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.99272
Table 1 Comparison of the recent effects between the two groups, n (%)
Group
CR
PR
SD
PD
Objective mitigation rate
Observation
(n = 58)
5 (8.62) 27 (46.55) 23 (39.66) 3 (5.17)32 (55.17)
Control (n = 58) 1 (1.72) 20 (34.48) 29 (50.00) 8 (13.79) 21 (36.21)
χ24.204
P value0.040
Table 2 Comparison of immune function indicators between the two groups before treatment (mean ± SD)
Group
CD3+ (%)
CD4+ (%)
CD8+ (%)
CD4+/CD8+
Treg cell (%)
NK cell (%)
Observation
(n = 58)
42.86 ± 4.8626.95 ± 3.1031.04 ± 2.080.87 ± 0.125.80 ± 1.0430.24 ± 4.85
Control (n = 58) 43.10 ± 4.9627.05 ± 3.1830.85 ± 2.120.88 ± 0.135.76 ± 1.0829.82 ± 4.90
t0.2630.1710.4870.4300.2030.464
P value0.7930.8640.6270.6680.8390.644
Table 3 Comparison of immune function indicators between the two groups after treatment (mean ± SD)
Group
CD3+ (%)
CD4+ (%)
CD8+ (%)
CD4+/CD8+
Treg cell (%)
NK cell (%)
Observation
(n = 58)
61.28 ± 5.84a38.84 ± 3.58a21.58 ± 2.08a1.81 ± 0.18a2.08 ± 0.65a21.26 ± 3.28a
Control (n = 58) 52.84 ± 5.80a33.10 ± 3.48a24.63 ± 2.12a1.34 ± 0.14a3.07 ± 0.72a24.95 ± 3.35a
t7.8098.7567.82115.6977.7735.994
P value< 0.001< 0.001< 0.001< 0.001< 0.001< 0.001
Table 4 Comparison of the two toxic groups, n (%)
Group
White blood cell reduction
Platelet reduction
Liver and kidney function injury
Level 1-2
Level 3-4
Level 1-2
Level 3-4
Level 1-2
Level 3-4
Observation (n = 58) 22 (37.93) 018 (31.03) 013 (22.41) 0
Control (n = 58) 31 (53.45) 3 (5.17) 20 (34.48) 2 (3.45) 23 (39.66) 0
χ24.9710.6114.028
P value0.0260.4350.045
Table 5 Comparison of the two toxic groups, n (%)
GroupNausea and vomiting
Hand-foot syndrome
Senses the abnormalities in peripheral nerves
Level 1-2
Level 3-4
Level 1-2
Level 3-4
Level 1-2
Level 3-4
Control (n = 58)21 (36.21) 1 (1.72) 3 (5.17) 06 (10.34) 0
Observation (n = 58)33 (56.90) 3 (5.17) 5 (8.62) 09 (15.52) 0
χ26.7590.1340.689
P value0.0090.7140.406